US2017258861A1PendingUtilityA1

Treatment of Herpes, Pseudomonas, Staph, and Hepatitis

Individually held — no corporate assignee on recordPriority: Feb 12, 1996Filed: May 28, 2017Published: Sep 14, 2017
Est. expiryFeb 12, 2016(expired)· nominal 20-yr term from priority
A61K 36/28A61K 31/14A61K 47/10A61K 31/4166A61K 47/186A61K 9/0014A61K 47/16A61K 31/045A61K 2300/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas , staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt surfactant, a skin protectant and an alcohol. The quaternary ammonium salt surfactant can comprise benzalkonium halide, preferably benzalkonium chloride. The skin protectant can comprise Allantoin. The alcohol can serve as a pain reliever and can comprise benzyl alcohol. The medicinal composition can also include other compounds, additives, herbal extracts and/or carriers. Desirably, the medicinal composition is maintained on the infected regions until external symptoms and physical manifestations of the symptoms resulting from herpes, pseudomonas , hepatitis, or staph substantially disappear from the infected regions.

Claims

exact text as granted — not AI-modified
1 . A composition comprising a quaternary ammonium salt surfactant and an herbal extract. 
     
     
         2 . The composition of  claim 1 , wherein the ammonium salt surfactant is alkyl dimethylbenzylammonium chloride, benzalkonium bromide, benzalkonium chloride, benzalkonium fluoride, alkylbenzyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, n-alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, n-dimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diaklyldimethylammonium chloride, octyldecyldimethylammonium chloride, lauryl dimethylbenzylammonium chloride, o-benzyl-p-chlorophenol, diethyldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, or alkylbenzyldimethylammonium chloride. 
     
     
         3 . The composition of  claim 1 , wherein the composition comprises from about 0.001% to about 0.99% by weight aqueous or dry benzalkonium chloride. 
     
     
         4 . The composition of  claim 1 , wherein the composition comprises from about 0.01% to about 99%  Echinacea purpurea.    
     
     
         5 . The composition of  claim 1 , wherein the composition further includes an herb or an herbal extract. 
     
     
         6 . The composition of  claim 1 , wherein the herb or herbal extract is from  Echinacea Purpurea.    
     
     
         7 . The composition of  claim 6 , wherein the herb or herbal extract from  Echinacea Purpurea  is about 1% to about 90% by weight of the composition. 
     
     
         8 . The composition of  claim 6 , wherein the herbal extract from  Echinacea Purpurea  is about 0.5% to about 60% by weight of the composition. 
     
     
         9 . The composition of  claim 1 , wherein the composition is applied to a patient topically, externally, internally, parenterally, or orally. 
     
     
         10 . The composition of  claim 1 , wherein the composition is applied to sores, rashes, skin conditions or symptoms resulting from herpes,  pseudomonas , staph or hepatitis, Epstein Barr, HIV, CMV, MRSA, VZV, Keratitis, or other infectious diseases. 
     
     
         11 . The composition of  claim 10 , wherein the composition is applied by one or more of the following methods comprising spraying, dabbing, dusting, swabbing, sponging, brushing, pouring, dispensing, covering, coating, swallowing, or injecting. 
     
     
         12 . The composition of  claim 1 , which is applied to a one or more of a patient's lips, mouth, oral mucosa, nasal mucosa, vaginal tissue, labial tissue, anal tissue, periacinal tissue, cutaneous tissue, ocular tissue, conjunctive, eye lids, or any location on or in the body. 
     
     
         13 . A method comprising providing the composition of  claim 1  to a patient suffering from cold sores caused by herpes, wherein the cold sores are resolved in about one day. 
     
     
         14 . The method of  claim 1 , wherein the cold sores are resolved in 19 to 24 hours.

Join the waitlist — get patent alerts

Track US2017258861A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.